cobas® eplex BCID-GP panel
cobas eplex blood culture identification gram-positive panel
The cobas eplex BCID panels provide broad coverage of organisms that can lead to sepsis along with their resistance genes.
The more you detect, the better you protect
The cobas eplex blood culture identification panels (BCID) broad coverage means that about 95% of currently identified bloodstream infections can be detected early, compared to other panels that detect significantly fewer sepsis-causing bacteria and fungi.
Infectious diseases, such as bloodstream infections that can lead to sepsis, respiratory infections and diarrhea are among the top causes of death worldwide.1,2
These and other infectious diseases can be considered syndromes (a group of symptoms that may not point to a specific causative agent) and may be difficult to diagnose using conventional diagnostic testing methods that look for a single or small number of disease-causing pathogens.
Explore the cobas eplex BCID panels benefits
Early identification helps improve patient outcomes
It is estimated that 20-30% of patients receive ineffective initial antibiotic therapy and the mortality rate for these patients increases up to 7.6% for every hour effective antibiotics are delayed.3,4
The cobas eplex BCID panels aid you in the identification of bacterial and fungal organisms as well as antibiotic resistance genes in about 90 minutes of blood culture bottle positivity, allowing treatment decisions to occur days earlier than with conventional methods. Unique solutions, like the cobas eplex system, can help to improve antimicrobial stewardship and optimize patient care.
The most comprehensive molecular blood culture panels
The cobas eplex BCID panels offer the broadest coverage5,6 of organisms and resistance markers that cause bloodstream infections (BSI) and can lead to sepsis, including anaerobes and multi-drug resistant organisms (MDRO), as well as common and emerging fungal pathogens (Table 1). The cobas eplex blood culture identification fungal pathogen panel (BCID-FP) was the first FDA-cleared multiplex molecular panel to include Candida auris, a multi-drug resistant fungal organism that is increasing in prevalence around the world.7
The cobas eplex BCID panels detect more of the organisms that cause bloodstream infections than other multiplex panels.
% organism inclusivity |
|||
| 5 US hospitals | Clinical study | Weighted average | |
| Number of samples (n) | 15,793 | 1,979 | 17,772 |
| cobas® eplex BCID panels | 94.1% | 93.6% | 94.0% |
| BioFire BCID | 84.3% | 86.6% | 84.5% |
| BioFire BCID v2 | 86.8% | 89.1% | 87% |
| Luminex Verigene BC¹ | 83.1% | 83.0% | 83.1% |
| Accelerate Pheno BC ID | 78.1% | 82.1% | 78.5% |
| Accelerate Pheno BC AST | 68.5% | 74.4% | 69.1% |
Resistance genes inform rapid clinical decision making
The cobas eplex BCID panels include 4 gram-positive and 6 gram-negative resistance genes that can be detected days earlier than conventional antimicrobial susceptibility tests (AST), enabling earlier escalation of therapy for resistant organisms or de-escalation of empirical antimicrobials in the case of common contaminants or when a narrower antibiotic is more appropriate. Rapid detection of antibiotic resistance genes when applied with local epidemiology of resistance, has been shown to have a high percent agreement with subsequent phenotypic susceptibility testing, allowing for recommendation of a targeted therapy earlier.8
Rapidly rule-out blood culture contamination
As much as 15 to 30% of positive blood cultures may be due to contaminants which can result in continuation of unnecessary antibiotics.9 The cobas eplex BCID panels are designed to allow you to more rapidly differentiate a contaminant from a true infection, enabling rapid de-escalation and discharge of patients with a bloodstream infection 2-3 days earlier than conventional methods. Common contaminants included on the cobas eplex BCID-GP panel but not on most competitor’s panels include:
- Bacillus subtilis
- Corynebacterium
- Cutibacterium acnes
- Micrococcus
- Lactobacillus
Comprehensive coverage of pathogens and resistance genes
Gram-positive organisms
Bacillus cereus group
Bacillus subtilis group
Corynebacterium
Cutibacterium acnes
Enterococcus
Enterococcus faecalis
Enterococcus faecium
Lactobacillus
Listeria
Listeria monocytogenes
Micrococcus
Staphylococcus
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus lugdunensis
Streptococcus
Streptococcus agalactiae (GBS)
Streptococcus anginosus group
Streptococcus pneumoniae
Streptococcus pyogenes (GAS)
Resistance genes
mecA
mecC
vanA
vanB
Pan targets
Pan gram-negative
Pan Candida
cobas® eplex system
True sample-to-answer solution
The cobas eplex system integrates the entire process from order-to-report to better realize the patient and laboratory benefits of rapid, multiplex molecular diagnostics.
You might be interested in
References
- Lozano R, et al., The Lancet 2012; 380: 2095–2128.
- Fact Sheet Sepsis. V2_Sepsis Fact Sheet. World Sepsis Day. Global Sepsis Alliance. Center for Sepsis Control & Care.
- IDSA: Better Tests Better Care, The Promise of Next Generation Diagnostics.
- Kumar, et al. (2006) Crit Care Med. 34 (6):1589-1596
- GenMark Blood Culture Identification - BCID- CE-IVD Package Insert
- BioFire Blood culture identification 2 (BCID2) panel [package insert RFIT-PRT-0841-02]. bioMerieux; Jun 2020.
- Tracking Candida auris:https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html (accessed 7/6/2022)
- Pogue, JM, et al. (2018) Antimicrob Agents Chemother: 62(5):e02538-17
- Murray, P. et. al. (2012), Crit Care Med,Current Approaches to the Diagnosis of Bacterial and Fungal Bloodstream Infections for the ICU.
